Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

There are two search modes available: simple and advanced. Simple search can include one or more words from the title, summary, keywords or full text, but does not allow the use of search operators. Advanced search allows to limit the number of search results by entering the search terms of different categories in the search window, as well as the use of Boolean search operators (AND, OR and AND NOT). In search results short formats of records are displayed and some data are displayed as links, which open a detailed description of the material (title link) or perform a new search (author or keyword link).

Help
Search in:
Options:
 


1851 - 1860 / 2000
First pagePrevious page182183184185186187188189190191Next pageLast page
1851.
1852.
Dynamics of CT visible pleural effusion in patients with pulmonary infarction
Igor Kocijančič, Jernej Vidmar, Marko Kastelic, 2018, original scientific article

Keywords: pulmonary infarction, pleural effusion, pulmonary embolism, CTA of pulmonary arteries
Published in DiRROS: 11.06.2024; Views: 328; Downloads: 206
.pdf Full text (919,01 KB)
This document has many files! More...

1853.
Comparison of anteroposterior and posteroanterior projection in lumbar spine radiography
Erna Alukić, Damijan Škrk, Nejc Mekiš, 2018, original scientific article

Keywords: lumbar spine radiography, PA projection, dose reduction, image quality
Published in DiRROS: 11.06.2024; Views: 360; Downloads: 180
.pdf Full text (354,25 KB)
This document has many files! More...

1854.
1855.
1856.
1857.
Electrochemotherapy with bleomycin of different types of cutaneous tumours in a ferret (Mustela putorius furo)
Joško Račnik, Tanja Švara, Marko Zadravec, Mitja Gombač, Maja Čemažar, Gregor Serša, Nataša Tozon, 2018, original scientific article

Abstract: Mast cell tumour, sebaceous gland adenoma, and less common squamous papilloma are skin tumours in ferrets (Mustela putorius furo), and early excisional surgery is usually the treatment of choice. The aim of our study was to investigate the effectiveness of electrochemotherapy (ECT), a new, minimally invasive non-surgical method, as first treatment option of different types of ferret skin tumours located on surgically difficult sites. Materials and methods A 5-year-old castrated male ferret with two cutaneous masses, presenting 4 months apart and a 7-year-old spayed female ferret with two cutaneous masses, that appeared simultaneously on two locations are presented. In the first patient, both masses were diagnosed as mast cell tumours, and in the second patient, squamous papilloma and sebaceous adenoma were diagnosed. One session of ECT with bleomycin injected intratumourally was applied in all tumours. Results Complete response (CR) of all tumours was obtained, without recurrence during observation period of 15 months after ECT for first tumour and 11 months after ECT of the tumour located on the right hock in first patient, and 8 months after treatment for the second patient. Conclusions In present study, ECT with bleomycin proved to be safe and effective against different cutaneous tumours in ferrets. Due of good results, low cost and relatively easy procedure, ECT could be the treatment of choice instead of surgery for the selected skin tumours in ferrets.
Published in DiRROS: 11.06.2024; Views: 345; Downloads: 219
.pdf Full text (1,59 MB)
This document has many files! More...

1858.
1859.
Locoregional disease control after external beam radiotherapy in 91 patients with differentiated thyroid carcinoma and pT4 tumor stage : a single institution experience
Nikola Bešić, Marta Dremelj, Gašper Pilko, 2018, original scientific article

Abstract: Locoregional recurrence is common in patients with locally advanced differentiated thyroid carcinoma (DTC). Our aim was to find out the rate of locoregional control of the disease after external beam radiotherapy (EBRT) of the neck and mediastinum in patients with DTC and pT4 tumor. Patients and methods Altogether 91 patients (47 males, 44 females, median age 61 years) with DTC had EBRT of the neck and mediastinum as part of the multimodal treatment of pT4 tumor (63 cases pT4a, 28 cases pT4b) from the year 1973 to 2015. Data on clinical factors, histopathology and recurrence were collected. Disease-free, disease-specific and overall survival was calculated. Results Median tumor size was 5 cm (range 1%30 cm). Out of 91 patients, 23 had distant and 38 regional metastases. A total or near-total thyroidectomy, lobectomy, subtotal thyroidectomy and lymph node dissection was performed in 70%, 14%, 2% and 30% of cases, respectively. Thirteen percent of patients were not treated with surgery. All patients had EBRT and 39 had chemotherapy. Radioiodine (RAI) ablation of thyroid remnant and RAI therapy was applied in 90% and 40% of cases, respectively. Recurrence was diagnosed in 29/64 patients without a persistent disease: locoregional and distant in 16 and 13 cases, respectively. Five-year and ten-year disease-free survival rate was 64% and 48%, respectively. Conclusions The majority of patients with DTC and pT4 tumors who were treated with EBRT of the neck and mediastinum region as part of multimodal treatment have long-lasting locoregional control of the disease.
Keywords: thyroid carcinoma, radiotherapy, survival, pathology
Published in DiRROS: 11.06.2024; Views: 394; Downloads: 119
.pdf Full text (300,30 KB)

1860.
Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells
Tanja Mesti, Nadia Bouchemal, Claire Banissi, Mohamed N. Triba, Carole Marbeuf-Gueye, Maja Čemažar, Laurence Le Moyec, Antoine F. Carpentier, Philippe Savarin, Janja Ocvirk, 2018, original scientific article

Abstract: Malignant gliomas are rapidly growing tumours that extensively invade the brain and have bad prognosis. Our study was performed to assess the metabolic effects of bevacizumab on the glioma cells carrying the IDH1 mutation, a mutation, associated with better prognosis and treatment outcome. Bevacizumab is known to inhibit tumour growth by neutralizing the biological activity of vascular endothelial growth factor (VEGF). However, the direct effects of bevacizumab on tumour cells metabolism remain poorly known. Materials and methods The immunoassay and MTT assay were used to assess the concentration of secreted VEGF and cell viability after bevacizumab exposure. Metabolomic studies on cells were performed using high resolution magic angle spinning spectroscopy (HRMAS). Results mIDH1-U87 cells secreted VEGF (13 ng/mL). Regardless, bevacizumab had no cytotoxic effect, even after a 72h exposure and with doses as high as 1 mg/mL. Yet, HRMAS analysis showed a significant effect of bevacizumab (0.1 mg/mL) on the metabolic phenotype of mIDH1-U87 cells with elevation of 2-hydroxyglutarate and changes in glutamine group metabolites (alanine, glutamate, glycine) and lipids (polyunsaturated fatty acids [PUFA], glycerophosphocholine, and phosphocholine). Conclusions In mIDH1-U87 cells, changes in glutamine group metabolites and lipids were identified as metabolic markers of bevacizumab treatment. These data support the possibility of a functional tricarboxylic acid cycle that runs in reductive manner, as a probable mechanism of action of bevacizumab in IDH1 mutated gliomas and propose a new target pathway for effective treatment of malignant gliomas.
Keywords: symptomatic pseudoprogression, atypical response, immunotherapy, lung cancer, idh1 mutation, malignant glioma, bevacizumab, metabolic fingerprint
Published in DiRROS: 11.06.2024; Views: 337; Downloads: 143
.pdf Full text (511,70 KB)

Search done in 0.62 sec.
Back to top